Modulation of epstein-barr virus latent membrane protein 1 activity by intrabodies

Intervirology

Volumn 50, Issue 4, 2007, Pages 254-263

  Fang, Chih Yeu ^a   Chiang, Chen Yi ^a   Pan, Yun Ru ^a   Tse, Ka Po ^b   Chang, Yu Sun ^b   Chang, Hwan You ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Cell motility; Epstein Barr virus; Latent membrane protein 1; Phage display; scFv Antibody

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; EPSTEIN BARR VIRUS; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VIVO STUDY; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; DOGS; EPITHELIAL CELLS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA; TRANSFECTION; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 34447641988     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101996     Document Type: Article

References (35)

1. Young LS, Rickinson AB: Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004;4:757-768.
2. Chen ML, Tsai CN, Liang CL, Shu CH, Huang CR, Sulitzeanu D, Liu ST, Chang YS: Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 1992;7:2131-2140.
3. Kaye KM, Izumi KM, Kieff E: Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993;90:9150-9154.
4. Baichwal VR, Sugden B: Transformation of Balb 3T3 cells by the BNLF-1 gene of Epstein-Barr virus. Oncogene 1988;2:461-467.
5. Wang S, Rowe M, Lundgren E: Expression of the Epstein Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1996;56:4610-4613.
6. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-1115.
7. Miller WE, Earp HS, Raab-Traub N: The Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor. J Virol 1995;69:4390-4398.
8. Tsai CN, Tsai CL, Tse KP, Chang HY, Chang YS: The Epstein-Barr virus oncogene product, latent membrane protein 1, induces the downregulation of E-cadherin gene expression via activation of DNA methyltransferases. Proc Natl Acad Sci USA 2002;99:10084-10089.
9. Yang X, Sham JS, Ng MH, Tsao SW, Zhang D, Lowe SW, Cao L: LMP1 of Epstein-Barr virus induces proliferation of primary mouse embryonic fibroblasts and cooperatively transforms the cells with a p16-insensitive CDK4 oncogene. J Virol 2000;74:883-891.
10. Huen DS, Henderson SA, Croom-Carter D, Rowe M: The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-560.
11. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M, Hammerschmidt W: Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 1999;18:3064-3073.
12. Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E, Mosialos G: Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1996;93:11085-11090.
13. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-399.
14. Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997;94:12592-12597.
15. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W: Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 1997;16:6478-6485.
16. Eliopoulos AG, Young LS: Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 1998;16:1731-1742.
17. Li HP, Chang YS: Epstein-Barr virus latent membrane protein 1: structure and functions. J Biomed Sci 2003;10:490-504.
18. McCafferty J, Griffiths AD, Winter G, Chiswell DJ: Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-554.
19. Cattaneo A, Biocca S: The selection of intracellular antibodies. Trends Biotechnol 1999;17:115-121.
20. Chi LM, Yu JS, Chang YS: Identification of protein kinase CK2 as a potent kinase of Epstein-Barr virus latent membrane protein 1. Biochem Biophys Res Commun 2002;294:586-591.
21. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, Allison TJ, et al: Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994;13:3245-3260.
22. Harrison JL, Williams SC, Winter G, Nissim A: Screening of phage antibody libraries. Methods Enzymol 1996;267:83-109.
23. Fang CY, Chang YS, Chow KP, Yu JS, Chang HY: Construction and characterization of monoclonal antibodies specific to Epstein-Barr virus latent membrane protein 1. J Immunol Methods 2004;287:21-30.
24. Sims RJ, 3rd, Liss AS, Gottlieb PD: Normalization of luciferase reporter assays under conditions that alter internal controls. Biotechniques 2003;34:938-940.
25. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA: Localization of the major NFkappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem 1997;272:19777-19784.
26. Kim KR, Yoshizaki T, Miyamori H, Hasegawa K, Horikawa T, Furukawa M, Harada S, Seiki M, Sato H: Transformation of Madin-Darby canine kidney (MDCK) epithelial cells by Epstein-Barr virus latent membrane protein 1 (LMP1) induces expression of Ets1 and invasive growth. Oncogene 2000;19:1764-1771.
27. Li G, Li XP, Peng Y, Liu X, Li XH: Effect of inhibition of EBV-encoded latent membrane protein-1 by small interfering RNA on EBVpositive nasopharyngeal carcinoma cell growth. Di Yi Jun Yi Da Xue Xue Bao 2004;24:241-246.
28. Biocca S, Pierandrei-Amaldi P, Cattaneo A: Intracellular expression of anti-p21ras single chain Fv fragments inhibits meiotic maturation of Xenopus oocytes. Biochem Biophys Res Commun 1993;197:422-427.
29. Tavladoraki P, Benvenuto E, Trinca S, De Martinis D, Cattaneo A, Galeffi P: Transgenic plants expressing a functional single-chain Fv antibody are specifically protected from virus attack. Nature 1993;366:469-472.
30. Rondon IJ, Marasco WA: Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. Annu Rev Microbiol 1997;51:257-283.
31. Worn A, Pluckthun A: Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 1998;37:13120-13127.
32. der Maur AA, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C, Escher D, Pluckthun A, Barberis A: Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem 2002;277:45075-45085.
33. Ohage E, Steipe B: Intrabody construction and expression. I. The critical role of VL domain stability. J Mol Biol 1999;291:1119-1128.
34. Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E, Mosialos G: Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996;16:7098-7108.
35. Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, Marasco WA: Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation. J Mol Biol 2004;335:193-207.